How is the Anti-Vascular Endothelial Growth Factor Therapeutics Market Poised for Growth: Trends and Opportunities Through 2034
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What key factors are powering the surge in the anti-vascular endothelial growth factor therapeutics market right now?
The market size for anti-vascular endothelial growth factor therapeutics has seen a slight increase in the past few years. There will be a growth from $12.2 billion in 2024 to $12.31 billion in 2025, with a compound annual growth rate (CAGR) of 1.0%. The growth witnessed in the historic period can be linked to the increase in age-related macular degeneration, the rising incidences of diabetic retinopathy, advancements in disease diagnosis for the retina, clinical success and effectiveness, as well as a shift towards outpatient treatment.
How fast Is the anti-vascular endothelial growth factor therapeutics market expected to grow, and what’s its future value?
Anticipated to sustain a consistent growth trajectory in the coming years, the anti-vascular endothelial growth factor therapeutics market is projected to reach a worth of “$13.49 billion in 2029, expanding at a compound annual growth rate of 2.3%. This growth in the projection period can be credited to an aging population and eye diseases, the extended use of these therapies for retinal disorders, advancements in following up treatment methods, heightened emphasis on proactive intervention, universal health endeavours and availability of medication. Foreseeable trends during this forecast period encompass increased usage in cancer treatment, heightened concentration on dual therapies in ophthalmology, the potential for biosimilar versions, studies on resistance mechanisms, and integration with imaging technologies.
Get your anti-vascular endothelial growth factor therapeutics market report here!
What are the leading drivers of growth in the anti-vascular endothelial growth factor therapeutics market?
The surge in the occurrence of diseases related to the eye is anticipated to spur the expansion of the anti-vascular endothelial growth factor therapeutics market. This increase links to the volume or percentage of people in a specific population diagnosed with or showing signs of particular eye ailments. The anti-vascular endothelial growth factor (VEGF) therapeutic measures help to lessen the occurrence of these ophthalmic diseases, treating conditions like wet age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. As an example, World Health Organization, a Swiss-based international public health organization reported in October 2022 that, globally, an estimated 2.2 billion individuals suffer from near or distance vision impairment, with a billion people experiencing near or distance vision issues. Additionally, out of these, 88.4 million have refractive errors, 94 million suffer from cataracts, 8 million deal with age-related macular degeneration, and nearly 3.9 million are diagnosed with diabetic retinopathy. Hence, the escalating prevalence of eye-related diseases contributes significantly to the growth of the anti-vascular endothelial growth factor therapeutics market.
What are the key segments defining the anti-vascular endothelial growth factor therapeutics market?
The anti-vascular endothelial growth factor therapeutics market covered in this report is segmented –
1) By Product: Eylea, Lucentis, Beovu
2) By Disease: Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration
3) By End Users: Hospitals, Clinics, Oncology Centers, Other End Users
Subsegments:
1) By Eylea: Indications, Dosage Forms
2) By Lucentis: Indications, Dosage Forms
3) By Beovu: Indications, Dosage Forms
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10683&type=smp
Who are the key players steering the development of the anti-vascular endothelial growth factor therapeutics market?
Major companies operating in the anti-vascular endothelial growth factor therapeutics market include F. Hoffmann-La Roche AG, Biogen Inc., Pfizer Inc., Coherus BioSciences Inc., Eli Lilly and Company, Bausch Health Companies Inc., Viatris Inc., Xbrane Biopharma AB, Bayer AG, Regeneron Pharmaceuticals Inc., Genentech Inc, Allergan Inc., Novartis AG, kyowa Kirin Co. Ltd., Amgen Inc., AstraZeneca plc, Merck & Co. Inc., Johnson & Johnson Private Limited, Sanofi S.A., AbbVie Inc., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc.
What emerging trends are influencing the growth of the anti-vascular endothelial growth factor therapeutics market?
In the anti-vascular endothelial growth factor therapeutics market, one significant trend that’s gaining traction is the continuous improvement in therapeutics. Companies in this market are utilizing these advanced therapeutics to maintain their market standing. For example, in May 2022, Ashvattha Therapeutics Inc., a U.S based clinical-stage biopharmaceutical firm, revealed phase 1 safety measurements for healthy subjects for subcutaneous anti-VEGF wet AMD (age-related macular degeneration) and DME (diabetic macular edema) candidates, designated as D-4517.2 therapy. This first-of-its-kind therapy is being developed to meet the inadequately addressed healthcare needs of DME conditions. Furthermore, an autoinjector is being designed for the self-delivery of D-4517.2 therapy. This autoinjector D-4517.2 will grant patients the ability to apply the medication themselves in the familiarity of their homes once a month.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10683
Which regions are most influential in expanding the anti-vascular endothelial growth factor therapeutics market?
North America was the largest region in the anti-vascular endothelial growth factor therapeutics market in 2024.Europe is expected to be the fastest-growing region in the global anti-vascular endothelial growth factor therapeutics market report during the forecast period. The regions covered in the anti-vascular endothelial growth factor therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Similar Reports By The Business Research Company:
Insecticides Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/insecticides-global-market-report
Crop Protection Chemicals Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/crop-protection-chemicals-global-market-report
Vector Control Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/vector-control-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
